Time-dependent up-regulation of endothelin-A receptors and down-regulation of endothelin-B receptors and nitric oxide synthase binding sites in the renal medulla of a rabbit model of partial bladder outlet obstruction: Potential clinical relevance

BJU International

Volumn 84, Issue 9, 1999, Pages 1073-1080

  Khan, M A ^a,b   Dashwood, M R ^a   Thompson, C S ^a   Mumtaz, F H ^a   Mikhailidis, D P ^a   Morgan, R J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Bladder outlet obstruction; Endothelin receptors; Nitric oxide synthase; Rabbit; Renal failure

Indexed keywords

CREATININE; ELECTROLYTE; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; NITRIC OXIDE SYNTHASE; RADIOLIGAND; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BLADDER NECK STENOSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ELECTROLYTE BLOOD LEVEL; ELECTRON MICROSCOPY; HISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY FAILURE; KIDNEY MEDULLA; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; UREA BLOOD LEVEL;

ANIMALS; BINDING SITES; DOWN-REGULATION; KIDNEY FAILURE, ACUTE; MALE; NITRIC OXIDE SYNTHASE; RABBITS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; TIME FACTORS; UP-REGULATION; URINARY BLADDER NECK OBSTRUCTION;

EID: 0032715056     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1999.00320.x     Document Type: Article

References (41)

1. 1 Napalkov P, Maisonneuve P, Boyle P. Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. Urology 1995; 46: 41-6
2. 2 O'Connor TL, Vaughan DE, Felsen D. In vivo cystometric evaluation of progressive bladder outlet obstruction in rats. J Urol 1997; 158: 631-5
3. 3 Walsh PC. Benign prostatic hyperplasia. In Walsh PC, Gittes RF, Perlmutter AD, Stamey TA, eds, Campbell's Urology, 5th edn. Philadelphia: Saunders, 1986: 1248-70
4. 4 Rodoman VE, Avdoshin VP, Andriukhin MI. Disorders of kidney function in patients with benign prostatic hyperplasia. Urologiia J Nefrologiia 1997; 6: 24-6
5. 5 Mandal AK, Baig M, Koutoubi K. Management of acute renal failure in the elderly. Treatment options. Drugs Aging 1996; 9: 224-50
6. 6 Sarmina I, Resnick MI. Obstructive uropathy in patients with benign prostatic hyperplasia. J Urol 1989; 141: 866-9
7. 7 Olbrich O, Woodford-Williams E, Irvine RE, Webster D. Renal function and prostatism. Lancet 1957; 1: 1322-6
8. 8 Murray T, Golberg M. Chronic interstitial nephritis: etiologic factors. Ann Intern Med 1975; 82: 453-9
9. 9 Feather S, Woolf AS, Gordon I, Risdon RA, Vesicoureteric reflux: all in the genes? Report of a meeting of physicians at the hospital for Sick Children, Great Ormond Street, London. Lancet 1996; 348: 725-8
10. 10 Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5
11. 11 Arai H, Hori S, Aramori L, Ohkubo H, Nakanishi S. Cloning and expression of cDNA encoding an endothelin receptor. Mature 1990; 348: 370-2
12. 12 Levin RE. Endothelins. N Engl J Med 1995; 333: 356-63
13. 12 Hirata Y, Emori T, Eguchi S et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993; 91: 1367-73
14. 14 Kohan DE. Endothelins in the normal and diseased kidney. Review. Am J Kid Dis 1997; 29: 2-26
15. 15 Chou SY, Dahhan A, Porush JG. Renal actions of endothelin: Interaction with prostacycline. Am J Physiol 1990; 2559: F645-52
16. 16 Simonson MS, Wann S, Mene P et al. Endothelin stimulates phospholipase C, Na/H exchange, c-fos expression and mitogenesis in rat mesangial cells. J Clin Invest 1989; 83: 708-12
17. 17 Kamphuis C, Yates NA, Mcdaugall JG. Differential blockade of the renal vasoconstrictor and diuretic response to endothelin-1 by endothelin antagonist. Clin Exp Pharmacol Physiol 1994; 21: 329-33
18. A. J Am Soc Nephrol 1994; 5: 1074-80
19. 19 Ruiz-Ortega M, Gomez-Game D, Alcazar R et al. Involvement of angiotensin II and endothelin in matrix protein production und renal sclerosis. J Hypertens 1994; 12: 551-8
20. 20 Bruzzi I, Benigni A. Endothelin is a key modulator of progressive renal injury: experimental data and novel therapeutic strategies. Clin Exp Pharmacol Physiol 1996; 4: 349-53
21. 21 Ehren I, Iversen H, Jansson O, Adolfsson J. Wiklund NP. Localization of nitric oxide synthase activity in the human lower urinary tract and its correlation with neuroeffector responses. Urology 1994; 44: 683-7
22. 22 Hocher B, Thone-Reineke C, Bauer C, Raschack M, Neumayer HH. The paracrine endothelin system: pathophysiology and implications in clinical medicine. Eur J Clin Chem Clin Biochem 1997; 35: 175-89
23. 23 Albertini M, Clement MG. The relationship between endothelins and eicosanoids in the vasculature. Prostgl Leucotr Essentl Fatty Acids 1998; 59: 1-10
24. 24 Smet PJ, Edyvane KA, Jonavicius J, Marshall VR. Distribution of NADPH-diaphorase-positive nerves supplying the human urinary bladder. J Autonom Nerv Syst 1994; 47: 109-13
25. 25 Persson K, Alm P, Johansson K, Larsson B, Andersson K-E. Nitric oxide synthase in pig lower urinary tract: immunohistochemistry, NADPH diaphorase histochemistry and functional effects. Br J Pharmacol 1993; 110: 521-30
26. G-nitro-arginine binding in rat brain. Neuropharmacol 1995; 34: 63-73
27. 27 Sullivan ME, Bell CRW, Dashwood MR et al. Autoradiographic localisation of nitric oxide synthase binding sites in normal and diabetic rat corpus cavernosum. Eur Urol 1996; 30: 506-11
28. 28 Buttyan R, Chen MW, Levin RM. Animal models of bladder outlet obstruction and molecular insights into the basis for the development of bladder dysfunction. Eur Urol 1997; 32: 32-9
29. A receptors. Er J Pharmacol 1994; 111: 4-6
30. 1,3,11/15]ET-1 in human heart. Br J Pharmacol 1992; 107: 637-9
31. 31 Sullivan ME, Dashwood MR, Thompson CS, Muddle JR, Mikhailidis DP, Morgan RJ, Alteration in endothelin B receptor sites in cavernosal tissue of diabetic rabbits: potential relevance to the pathogenesis of erectile dysfunction. J Urol 1997; 158: 1966-72
32. 32 El Nahas AM. Progression of renal scarring; A balancing act. In Grunfeld J-P, Bach JF, Kreis H, Maxwell MH, eds, Advances in Nephrology, Vol 27, Chapt 5. London: Mosby, 1998: 67-84
33. 33 Simonson MS. Endothelins: multifunctional renal peptides. Physiol Rev 1993; 73: 175-411
34. 34 Rubanyi GM, Botelho LHP. Endothelins. FASEB J 1991; 5: 2713-20
35. 35 Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; ii: 670-8
36. 36 Richard V, Hogie M, Clozel M, Loffler BM, Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation 1995; 91: 771-5
37. 37 Savage C. The biology of the glomerulus: endothelial cells. Kidney Int 1994; 45: 314-9
38. 38 Kanse SM, Wijelath E, Kanthou C, Newman P, Kakkar VV. The proliferative responsiveness of human vascular smooth muscle cells to endothelin correlates with endothelin receptor density. Lab Invest 1995; 72: 376-82
39. 39 Desmouliere A, Geinoz A, Gabbiani F et al. Transforming growth factor-β 1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing fibroblasts. J Cell Biol 1993; 122: 1103-11
40. 40 Walton G, Buttyan R, Garcia-Montes E, Olsson CA, Hensle TW, Sawevuk IS. Renal growth factor expression during early phase of experimental hydronephrosis. J Urol 1992; 148: 510-4
41. 41 Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H. effect of a specific endothelin receptor-A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 1995; 44: 895-9